amantadine / Generic mfg. - LARVOL DELTA

Amantadine: a first option for symptomatic relief in young-onset Parkinson's disease? (PubMed, Parkinsonism Relat Disord) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database. (PubMed, Arq Neuropsiquiatr) - "The most used medications were pramipexole (45.6%), amantadine (26.0%), and entacapone (17.1%).The present study provides valuable insights into the demographic and clinical profile of PD patients in Brazil, highlighting frequent procedures and treatment patterns. A key limitation is the non-capture of basic PD medications, such as levodopa, which are often dispensed outside the analyzed datasets. These findings underscore the need for improved data integration and access to comprehensive PD care within the public health system."

HEOR • Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

AmantadineLC: Amantadine Therapy for Cognitive Impairment in Long COVID (clinicaltrials.gov) - P2 | N=64 | Completed | Sponsor: Ohio State University | Recruiting ➔ Completed

Trial completion • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease

Strategies for improving recovery of consciousness after acute brain injury. (PubMed, Curr Opin Crit Care) - "These developments collectively highlight the need for integrated multimodal assessment and multilevel interventions, pointing toward a future of personalized, precision medicine for arousal promotion that offers tangible hope for improving patient recovery outcomes and quality of life."

Journal • CNS Disorders • Critical care • Vascular Neurology

Amantadine derivative Amt-1 enhances antiviral defense against influenza A virus via Nrf2/HO-1 pathway. (PubMed, Mol Pharmacol) - "SIGNIFICANCE STATEMENT: Amt-1 exhibits a dual mechanism of action, including direct antiviral effects through residual M2 affinity and host-directed anti-inflammatory activity mediated by the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 and nuclear factor kappa-B pathways. This balanced immunomodulatory and antiviral profile presents a distinct approach in adamantane-based drug development."

Journal • Infectious Disease • Influenza • Oncology • Respiratory Diseases • HMOX1 • IL1B • IL6 • NFE2L2 • TNFA

Behavioral abnormalities in older patients with chronic renal function decline following administration of compound paracetamol and amantadine hydrochloride capsules. (PubMed, J Med Case Rep) - "The central toxicity of amantadine is significantly enhanced in older patients with renal insufficiency, and chlorphenamine may increase the risk of delirium. The risks associated with using this medication in older patients suffering from the common cold far outweigh the benefits, warranting cautious use in clinical practice; adverse reactions should be managed with prompt discontinuation of the medication and hydration to facilitate drug clearance. This study provides crucial warnings about medication safety in the older population."

Journal • CNS Disorders • Nephrology • Renal Disease • Respiratory Diseases

Rare case of WNK3-related neurodevelopmental disorder (Prieto Syndrome): Expanding the phenotype (ACMG 2026) - "Current medications include amantadine, buspirone, clonidine, and olanzapine. The canonical splice site variant was predicted to result in a null allele in a gene for which to loss of function is a known mechanism of disease. The intron 18 variant is not present in gnomAD nor previously published."

Clinical • Neurodevelopmental • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Constipation • Depression • Developmental Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Infectious Disease • Insomnia • Mental Retardation • Mood Disorders • Obesity • Otorhinolaryngology • Psychiatry • Sleep Disorder

The persisting puzzle of OFF time in advanced Parkinson's disease. (PubMed, Brain) - "The complexity of managing motor fluctuations is further highlighted by the effectiveness of various non-dopaminergic adjunctive therapies for reducing OFF time in levodopa-treated patients, as shown by placebo-controlled clinical trials with adjunctive istradefylline, amantadine, zonisamide, and deep brain stimulation. For achieving better control of OFF time in advanced Parkinson's disease, there is a need for discovering therapeutic strategies acting beyond the limits of today's dopaminergic therapies. Modeling brain circuitry with tools like deterministic neural-computational analysis may provide valuable pharmacological and electrophysiological insights for better understanding of motor fluctuations and the choice of appropriate therapeutic targets."

Clinical • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Prolonged Tardive Dyskinesia Induced by Long-Acting Paliperidone Palmitate in Schizophrenia: A Case Report. (PubMed, Am J Case Rep) - "Dose reduction to 350 mg was ineffective; the long-acting injection was stopped in June 2019, and aripiprazole 10 mg/day was started. Adjuncts (trihexyphenidyl, amantadine, and intermittent benzodiazepines) provided only limited benefit...Over 6 years without vesicular monoamine transporter 2 (VMAT-2) inhibitors, her dystonia lessened but persisted, and she was discharged on clozapine and fluvoxamine...Given therapeutic limits, variable prognosis, and the 3-month formulation's extended pharmacokinetics, clinicians should maintain high suspicion, minimize dopamine-receptor-blocking exposure, and individualize care, considering timely VMAT-2 inhibitors or clozapine, plus structured long-term motor monitoring and shared decision-making. This report highlights the presentation of tardive dyskinesia as a complication of antipsychotic medication and the approach to management of this iatrogenic syndrome."

Journal • CNS Disorders • Dystonia • Movement Disorders • Psychiatry • Schizophrenia

AMANTADINE FOR LEVODOPA INDUCED DYSKINESIAS IN PD: PREVALENCE, CLINICAL CORRELATES, AND TREATMENT OUTCOMES IN THE PPMI STUDY COHORT (ADPD 2026) - "Amantadine use was reported for 29% of subjects with dyskinesia, a majority with lower than recommended doses. Approximately one third discontinued amantadine. MDS-UPDRS-4 (Complications of therapy) was independent of general PD-severity measures."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

DYNAMIC CHANGES IN THE MOTOR SPHERE AGAINST THE BACKGROUND OF THE USE OF AMANTADINE IN PATIENTS WITH MULTIPLE SCLEROSIS (ADPD 2026) - "Adding amantadine to the treatment regimen of patients with multiple sclerosis allows for improved motor activity by reducing muscle tone. Amantadine accelerates the recovery of motor functions, improves cognitive functions and quality of life in patients with multiple sclerosis."

Clinical • CNS Disorders • Multiple Sclerosis • Otorhinolaryngology

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease. (PubMed, Res Sq) - "Twenty drugs showed consistent protective associations, with four emerging as highly reproducible across both networks, the metabolic agents liraglutide and empagliflozin and the neuroactive agents entacapone and amantadine. Metabolic drugs produced the strongest benefits in individuals with diabetes, obesity, or cardiovascular disease, whereas neuroactive drugs provided broadly consistent protection across most subgroups.CauReL is available as an open source Python package with a companion web server for direct application to new cohorts or disease settings (https://caurel.site/). This work delivers a scalable and interpretable framework for prioritizing repurposable drugs and designing targeted clinical trials for the patients most likely to benefit."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

An overview of the current management and emerging therapies of Multiple system atrophy. (PubMed, Expert Rev Neurother) - "Motor symptom interventions are primarily levodopa-based, yielding partial and transient responses, especially in MSA-P, whereas dopaminergic agonists, MAO-B inhibitors, amantadine, and device-aided therapies provide a limited or short-lived benefit...Management of MSA remains largely symptomatic. Multimodal treatment and integration of rehabilitative and non-pharmacological strategies are critical, while ongoing trials in neuroprotection and neuromodulation represent key avenues to improve long-term outcomes."

Journal • Review • CNS Disorders • Gastrointestinal Disorder • Hypotension • Mental Retardation • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sexual Disorders • Sleep Disorder

Repurposing of FDA-Approved Antiviral Drugs Against Monkeypox Virus: Comparative In Vitro Screening and Structure Based In Silico Studies. (PubMed, Pharmaceuticals (Basel)) - "Twenty-three FDA-approved drugs, including Abacavir, Acyclovir, Amantadine, Chloroquine, Daclatasvir, Dolutegravir, Entecavir, Favipiravir, Hydroxychloroquine, Lamivudine, Molnupiravir, Nevirapine, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Sofosbuvir, Tenofovir, Valaciclovir, Valganciclovir, Velpatasvir, Zanamivir, and Zidovudine, were screened for potential anti-monkeypox activity in vitro...The employed computational methods indicate that remdesivir demonstrated superior binding patterns with elevated scores and stable complexes throughout the simulation. Our findings showed that Remdesivir therapeutic compound is potent against the tested strain of MPXV, and exhibited a robust binding affinity for Thymidylate Kinase, A42R Profilin-Like Protein, and VACV D13 enzymes, and thus may potentially be utilized as antiviral for the treatment of monkeypox virus."

FDA event • Journal • Preclinical • Infectious Disease

Sydenham Chorea With Elevated Interleukin-12 Levels Responsive to Plasmapheresis and Immunotherapy. (PubMed, Cureus) - "She was treated with intravenous immunoglobulin, oral prednisone, and amantadine, resulting in full symptom resolution. Chronic elevation of IL-12 differs from previously published findings, which describe elevation only during the acute phase of the disease. Intensive immunosuppressive treatment during the acute phase, along with adherence to antibiotic therapy, may have contributed to the full resolution of her chorea."

Journal • Immunology • Infectious Disease • Movement Disorders • Otorhinolaryngology • IL12A

Adding Amantadine to Pregabalin on Occurrence of Post-thoracotomy Pain Syndrome (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Cairo University | Recruiting ➔ Completed

Trial completion • Musculoskeletal Pain • Pain

Severe Delirium Caused by Short-Term Administration of Compound Paracetamol and Amantadine Hydrochloride Capsules in an Elderly Patient With Extremely Low Body Weight. (PubMed, Cureus) - "Following medication discontinuation, full fluid replacement, and symptomatic treatment with low-dose olanzapine (2.5-5 mg/day), the patient's mental and behavioral symptoms completely resolved by day 11, with the Nursing Delirium Screening Scale (Nu-DESC) score decreasing from 10 to 0. These factors can lead to rapid drug accumulation, even in patients with normal renal function. Therefore, clinicians should exercise caution in prescribing amantadine-containing medications to high-risk populations and enhance medication safety education."

Journal • CNS Disorders • Geriatric Disorders • Infectious Disease • Respiratory Diseases

De novo design of small molecule-regulated protein oligomers. (PubMed, Science) - "We designed protein homotrimers regulated by the Food and Drug Administration (FDA)-approved drug amantadine and further designed amantadine-responsive heterodimers and heterotrimers...We demonstrated their broad applicability in controlling protein localization, membraneless condensate formation, and gene expression. Our approach opens new avenues for designing small molecule-responsive proteins and expands the chemogenetic toolkit for manipulating complex biological processes."

Journal

Supramolecularly gated enzymes: On-demand activity switching via host-guest competition for precision tumor therapy. (PubMed, Mater Today Bio) - "This system utilizes the high-affinity interaction between cucurbit[7]uril (CB[7]) and amantadine (Ad) to precisely control enzyme function...Furthermore, we extended this approach to enzyme/prodrug therapy, achieving localized prodrug activation and targeted cell death while minimizing off-target effects and systemic toxicity. Thus, this non-covalent, reversible regulation of enzyme activity represents a significant advancement over traditional methods, offering a versatile and biocompatible tool for studying protein function and developing targeted therapeutic strategies."

Journal • Oncology • CAT

Reply to Willoughby on Demise of the Milwaukee Protocol for Rabies. (PubMed, Clin Infect Dis) - No abstract available

Journal

Deep learning, deeper relief: pipeline toward tailored analgesia for experimental animal models. (PubMed, Front Immunol) - "Our findings indicate that commonly used analgesics, such as tramadol and acetaminophen, not only interfere with immune cell recruitment and NF-κB activation but also skew the differentiation of epithelial stem cells into goblet cells, affecting epithelial functions even after short exposures. We then predicted and identified the signaling pathways that are impacted by amantadine treatment. In summary, our proposed pipeline facilitates a shift from one-size-fits-all analgesics to a precision medicine approach that considers the unique molecular interactions associated with each model."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Pain

Beyond the Impact: Emerging Therapies Shaping the Future of Post-Concussion Recovery. (PubMed, Int J Neurosci) - "Medicines like amantadine and zolpidem may help treat certain symptoms...This review looks at new information and trends to help doctors and researchers understand the latest ways to treat ongoing symptoms after a concussion. It also aims to guide future studies in this important field."

Journal • Review

Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Neurodegener Dis Manag) - "This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use."

Journal • Retrospective data • Review • CNS Disorders • Fatigue • Insomnia • Multiple Sclerosis • Sleep Disorder

Bridging the gap: Acute amantadine augments the neurorehabilitative efficacy of delayed and abbreviated environmental enrichment in a pediatric traumatic brain injury model. (PubMed, Brain Res) - "Overall, these findings reveal that acute AMT treatment augments the efficacy of delayed and abbreviated EE, particularly in cognitive and affective domains, which support the hypothesis. This temporally staged combination therapy may more accurately model clinical care and lead to greater improvement after TBI."

Journal • CNS Disorders • Pediatrics • Vascular Neurology • CA3

Identification of Rat Monocarboxylate Transporter 9 as a Low-Affinity Transporter of 1-Methyl-4-phenylpyridinium and Amantadine. (PubMed, Biol Pharm Bull) - "Despite the expression of MCT9 in the BRB, it is suggested that the contribution of MCT9 to amantadine transport across the BRB is minor. In conclusion, our study first identified the cationic compounds, namely, MPP+ and amantadine, as substrates transported by MCT9."

Journal • Preclinical